Globus Medical, Inc.
GMED Healthcare Medical Devices
Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- +19.3%
- Free cash flow
- +10.1%
Quarter to September 2026, against a year earlier
Follow GMED
Alert me
Globus Medical, Inc. (GMED) P/E ratio
As of 5 November 2026, Globus Medical, Inc. (GMED) trades at a P/E ratio of 19.5×. Over the past ten years it has ranged from 16.9× (November 2016) to 246× (August 2024); the current reading is higher than 8% of that period. That is below the Medical Devices industry median of 25.6× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 21.9× | (80.11%) |
| FY2024 | 110× | 144.79% |
| FY2023 | 45.1× | 16.38% |
| FY2022 | 38.7× | (20.65%) |
| FY2021 | 48.8× | (22.21%) |
| FY2020 | 62.7× | 68.28% |
| FY2019 | 37.3× | 37.77% |
| FY2018 | 27.1× | (29.82%) |
| FY2017 | 38.5× | 67.92% |
| FY2016 | 23.0× | (2.64%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 18.1× | (9.09%) |
| Jun 2026 | 19.9× | 0.48% |
| Mar 2026 | 19.8× | (9.71%) |
| Dec 2025 | 21.9× | 19.51% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRKR Bruker Corporation compare | n/m |
| GKOS Glaukos Corporation compare | n/m |
| TXG 10x Genomics compare | n/m |
| BIO Bio-Rad Laboratories, Inc. compare | 9.7× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 9.9× |
| GMED Globus Medical, Inc. | 19.5× |
| PODD Insulet Corporation compare | 25.2× |
| SNN Smith & Nephew SNATS, Inc. compare | 38.9× |
| PEN Penumbra, Inc. compare | 80.3× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on GMED
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement